Method for producing Fc-containing molecule modification reagent

By adjusting the reaction conditions and using Sephadex G-10 chromatography column, the problem of difficult separation of hydrolysate by-products in antibody-modified linker production is solved, and high-purity and high-yield antibody-modified linker production is achieved.

CN118922433APending Publication Date: 2024-11-08NIHON MEDI PHYSICS CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026826.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-11
Filing Date
2023-03-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the manufacture of antibody-modified linkers, existing methods make it difficult to isolate hydrolysate by-products, resulting in difficulty in purification, and low recovery rates of high-temperature reactions and reverse phase chromatography columns, which are not suitable for large-scale production.

Method used

By adjusting the reaction conditions, using a base catalyst stronger than pyridine, the reaction temperature was reduced, and purification was performed using a Sephadex G-10 chromatography column to shorten the reaction time to improve the yield and purity of the antibody-modified linker.

Benefits of technology

The production of high-purity antibody-modified linkers is achieved, the hydrolysate content is reduced, the yield and recovery rate is improved, and it is suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922433A_ABST
    Figure CN118922433A_ABST
Patent Text Reader

Abstract

The present invention pertains to a method for producing an Fc-containing molecule modifying agent, the method comprising reacting a protein or peptide with a crosslinking agent in the presence of a base having a stronger basicity than pyridine, and bonding an amino group in the protein or peptide with the crosslinking agent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing a Fc-containing molecule modification agent and a method for producing a complex using the Fc-containing molecule modification agent. Background Art

[0002] Antibodies have long been used to detect target molecules in various research and development, and are extremely important in the industry as detection reagents and diagnostic drugs. In addition, antibodies have also attracted attention as pharmaceuticals for the treatment of diseases due to their high specificity for their target molecules.

[0003] As a site-specific chemical modification for imparting function without affecting the specificity of the antibody for the target molecule, the inventors of the present application have so far reported the following technology: introducing an amino acid capable of binding to a cross-linking agent into a peptide that specifically or selectively binds to the antibody (hereinafter also referred to as an IgG-binding peptide), modifying the amino acid using a cross-linking agent, thereby preparing an IgG-binding peptide site-specifically modified with a cross-linking agent, and using the IgG-binding peptide to site-specifically modify the antibody (Patent Document 1).

[0004] IgG binding peptides are peptides that can specifically bind to the Fc region of IgG. The inventors of the present application have so far developed CCAP (Chemical conjugation by affinity peptide) reagents as antibody labeling reagents using Fc binding peptides such as Z33 peptide and Z34C peptide. In the CCAP reagent, the lysine residue, cysteine ​​residue, aspartic acid residue, glutamic acid residue, 2-aminosuberic acid, diaminopropionic acid, arginine residue or the amino group of the first amino acid present in the Fc binding peptide is modified with a reactive functional group. The CCAP method, which binds the CCAP reagent to the antibody, is a method that can site-specifically modify the antibody with a covalent bond, and its application in radiopharmaceuticals and antibody-drug complexes is currently being studied (patent documents 1 to 3).

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: International Publication No. 2017 / 217347

[0008] Patent Document 2: International Publication No. 2016 / 186206

[0009] Patent Document 3: International Publication No. 2018 / 230257 Summary of the invention

[0010] The inventors of the present application have discovered that, when producing an IgG-binding peptide site-specifically modified with a cross-linking agent (hereinafter also referred to as an antibody-modified linker), in conventional methods such as the method described in Patent Document 1, a hydrolyzate of the antibody-modified linker is generated as a by-product when the cross-linking agent is reacted with the IgG-binding peptide, and that since the hydrolyzate of the antibody-modified linker has physical properties similar to those of the antibody-modified linker, it is difficult to separate the two using purification methods such as high performance liquid chromatography.

[0011] Therefore, it is desired to develop a method for producing an antibody-modified linker that maintains the yield of the antibody-modified linker at the same level as in the prior art and reduces the generation of hydrolyzates that are difficult to separate.

[0012] In addition, there are several problems in the production method of CCAP reagents that have been succinimidyl glutaryl (SG) by reacting IgG binding peptides (IgG-BP) or Z33, Z34C peptides used in the CCAP method with the cross-linking reagent disuccinimidyl glutarate (DSG). One is that the reaction requires a high temperature (50°C) and a reaction time of 2 hours, and the other is that the recovery rate is low because a reverse phase chromatography column is used for purification, which is not suitable for large-scale production.

[0013] The inventors of the present application have conducted intensive research in view of the above-mentioned problems, and as a result, have discovered the following production method: As a first embodiment of the present invention, by appropriately selecting the reaction conditions (type of base and reaction temperature) when reacting an IgG binding peptide with a cross-linking agent, it is possible to successfully maintain the yield of the antibody-modified linker at the same level as before and reduce the content of the hydrolyzate of the antibody-modified linker as a by-product, thereby obtaining an antibody-modified linker with higher purity.

[0014] In addition, a second embodiment of the present invention aims to provide a method for producing an antibody labeling reagent which can obtain the antibody labeling reagent in a short time and with a high yield.

[0015] To solve this problem, the inventors of the present application improved the reaction method and purification method of IgG binding peptide or Z33, Z34C peptide and DSG, and as a result, established a method for obtaining CCAP reagent in a short time and with high yield.

[0016] In the existing method, the reaction of IgG binding peptide (IgG-BP) or Z33, Z34C peptide and DSG is carried out in DMSO containing 1% pyridine at 50°C for 2 hours. Under such conditions, there is a concern that side reactions such as racemization of amino acids in the peptide may occur, so a method for carrying out the reaction under milder conditions is required. The results of the research conducted by the inventors of the present application found that the reaction was accelerated dramatically by using other base catalysts instead of 1% pyridine. As described later, the peptide can be modified with a yield of nearly 100% in just 15 minutes.

[0017] Another improvement of the second embodiment of the present invention is to change the purification method of the SG-treated CCAP reagent. After the peptide and DSG are reacted, it is necessary to remove the excess DSG, which was previously performed using a reverse phase chromatographic column. However, the reverse phase chromatographic column has problems such as low recovery and difficulty in scale-up. For this reason, the size exclusion chromatography method using a Sephadex G-10 chromatographic column was changed to achieve the omission of steps and the improvement of recovery.

[0018] The method for producing a Fc-containing molecule modification reagent of the present invention comprises: reacting a protein or a peptide with a cross-linking agent in the presence of a base having a stronger alkalinity than pyridine, so that the amino groups in the protein or the peptide are bonded to the cross-linking agent. It should be noted that in the present invention, "antibody modification linker" and "antibody labeling reagent" are included in "Fc-containing molecule modification reagent".

[0019] Another embodiment of the present invention provides a method for producing a complex, which comprises: a linker modification step, implementing the method for producing an Fc-containing molecule modification reagent of the present invention to obtain an Fc-containing molecule modification reagent; and a complexing step, mixing the above-mentioned Fc-containing molecule modification reagent and an Fc-containing molecule, allowing the above-mentioned Fc-containing molecule modification reagent to react with the side chain terminal amino group of the amino acid constituting the above-mentioned Fc-containing molecule, to obtain a complex of the above-mentioned Fc-containing molecule modification reagent and the above-mentioned Fc-containing molecule.

[0020] According to the production method of the first embodiment of the present invention, the yield of the antibody-modified linker can be maintained at the same level as in the past, and the content of the hydrolyzate of the antibody-modified linker can be reduced. In other words, the antibody-modified linker can be produced at a high purity.

[0021] According to the production method of the second embodiment of the present invention, an antibody-labeled reagent can be obtained in a short time and with a high yield. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] [ Figure 1 ] is a diagram showing the pathway of SGation reaction of IgGBP-N3-RRR peptide.

[0023] [ Figure 2] is a graph showing the results of reverse phase HPLC analysis of IgGBP-N3-RRR peptide before (A) and after (B) the SGization reaction.

[0024] [ Figure 3 ] is a graph showing the results of size exclusion chromatography (A) of the SG-forming reaction product of IgGBP-N3-RRR peptide and the results of reverse phase HPLC analysis (B) after purification.

[0025] [ Figure 4 ] is a diagram showing the pathway of the SGylation reaction of the Z33-38 azidated peptide.

[0026] [ Figure 5 ] is a diagram showing the results of reverse phase HPLC analysis of Z33-38 azidation peptide before (A) and after (B) the SG reaction.

[0027] [ Figure 6 ] is a graph showing the results of size exclusion chromatography (A) of the SG-ylation reaction product of the Z33-38 azidated peptide and the results of reverse phase HPLC analysis (B) after purification. DETAILED DESCRIPTION

[0028] Unless otherwise specified, the terms used in this specification may be used with the meanings generally used in the technical field.

[0029] In the present invention, "Fc-containing molecules" only need to contain the Fc region of an antibody, and include polypeptides obtained by fusion of the Fc region with other polypeptides, such as antibodies, etc. As Fc-containing molecules, full-length antibodies, antibody fragments, or mutants may be used.

[0030] In the present invention, "Fc" generally refers to a region of an antibody molecule that includes two polypeptide chains consisting of a hinge portion or a portion thereof, a CH2 domain, and a CH3 domain, but is not particularly limited thereto and may not contain a hinge portion or a portion thereof. Fc can be obtained by partially digesting IgG with a protease.

[0031] In the following embodiments, the present invention is described mainly by taking antibodies as examples as Fc-containing molecules, but the present invention is not limited to this. The antibody-modified linker described in the first embodiment can be used as a linker for modifying Fc-containing molecules, and the antibody labeling reagent described in the second embodiment can be used as a labeling reagent for Fc-containing molecules.

[0032] (First embodiment)

[0033] The first embodiment of the present invention provides a method for producing an antibody-modified linker, which is a method for producing an antibody-modified linker by reacting an IgG binding peptide with a cross-linking agent, characterized in that the cross-linking agent is a cross-linking agent having a succinimide group that can bind to the side chain terminal amino group of the amino acid residue constituting the IgG binding peptide, and the reaction is carried out in the presence of a tertiary amine with a stronger alkalinity than pyridine and below room temperature. Hereinafter, it is also referred to as the method for producing an antibody-modified linker of the first embodiment.

[0034] 1. Method for producing antibody-modified linkers

[0035] The first embodiment of the present invention provides a method for producing an IgG binding peptide (a peptide that specifically or selectively binds to an antibody) that has been site-specifically modified with a crosslinker. In the first embodiment of the present invention, the IgG binding peptide that has been site-specifically modified with a crosslinker is also referred to as an antibody-modified linker.

[0036] <IgG binding peptide>

[0037] The "IgG" used in the first embodiment of the present invention refers to IgG of mammals such as humans and primates such as chimpanzees, experimental animals such as rats, mice and rabbits, domestic animals such as pigs, cattle, horses, sheep and goats, and pets such as dogs and cats, and preferably refers to human IgG (IgG1, IgG2, IgG3 or IgG4). The IgG in the first embodiment of the present invention is more preferably human IgG1, IgG2 or IgG4, or rabbit IgG, and particularly preferably human IgG1, IgG2 or IgG4.

[0038] In one embodiment, the IgG-binding peptide used in the first embodiment of the present invention comprises an amino acid sequence consisting of 13 to 17 amino acid residues represented by the following formula I, and is capable of binding to human IgG.

[0039] (X) 1-3 -C-(X)2-H-(Xaa1)-G-(Xaa2)-LVWC-(X) 1-3 (I)

[0040] (wherein each X is independently any amino acid residue except cysteine,

[0041] C is a cysteine ​​residue,

[0042] H is a histidine residue,

[0043] Xaa1 is a lysine residue,

[0044] G is a glycine residue,

[0045] Xaa2 is a glutamic acid residue, a glutamine residue or an asparagine residue,

[0046] L is a leucine residue,

[0047] V is a valine residue, and

[0048] W is a tryptophan residue. )

[0049] In the above formula, the N-terminal or C-terminal is denoted as (X) 1-3 The expression (X) means that there are 1 to 3 consecutive independent arbitrary amino acid residues X except cysteine ​​(C or Cys), and the amino acid residues constituting the residues are the same or different residues, but preferably the sequence of 3 residues is not the same. Similarly, (X)2 also means that there are 2 consecutive independent arbitrary amino acid residues X except cysteine ​​(C or Cys), and the amino acid residues constituting the residues are the same or different residues, but preferably the sequence of the 2 consecutive amino acid residues is not the same residue.

[0050] The two cysteine ​​residues of formula I may be bonded by a disulfide bond to form a cyclic peptide, usually by a disulfide bond. Alternatively, in the peptide of formula I, the thioether groups of the two cysteine ​​residues may be linked by a group represented by the following formula.

[0051] [Chemical formula 1]

[0052]

[0053] The wavy line portion in the above formula refers to the bonded portion with the thioether group. This group is more stable to reduction reactions, etc. than a conventional disulfide bond. Such a peptide can be synthesized according to the method described in WO2016 / 186206 and WO2017 / 217347, for example.

[0054] Several specific examples of the IgG-binding peptide of Formula I are listed in the following 1) to 18), but the peptide is of course not limited to these specific examples.

[0055] 1) DCAYH(Xaa1)GELVWCT(sequence number 116),

[0056] 2) GPDCAYH(Xaa1)GELVWCTFH(sequence number 117),

[0057] 3)RCAYH(Xaa1)GELVWCS(serial number 118),

[0058] 4)GPRCAYH(Xaa1)GELVWCSFH(sequence number 119),

[0059] 5)SPDCAYH(Xaa1)GELVWCTFH(sequence number 120),

[0060] 6) GDDCAYH(Xaa1)GELVWCTFH(sequence number 121),

[0061] 7)GPSCAYH(Xaa1)GELVWCTFH(serial number 122),

[0062] 8) GPDCAYH(Xaa1)GELVWCSFH(sequence number 123),

[0063] 9)GPDCAYH(Xaa1)GELVWCTHH(sequence number 124),

[0064] 10) GPDCAYH(Xaa1)GELVWCTFY(sequence number 125),

[0065] 11)SPDCAYH(Xaa1)GELVWCTFY(sequence number 126),

[0066] 12)SDDCAYH(Xaa1)GELVWCTFY(serial number 127),

[0067] 13)RGNCAYH(Xaa1)GQLVWCTYH(sequence number 128),

[0068] 14)G(Xaa3)DCAYH(Xaa1)GELVWCT(Xaa3)H(serial number 129)

[0069] 15) DCTYH(Xaa1)GNLVWCT(serial number 130),

[0070] 16) DCAYH(Xaa1)GNLVWCT(sequence number 131),

[0071] 17) DCTYH(Xaa1)GELVWCT (SEQ ID NO: 132), and

[0072] 18)DCAWH(Xaa1)GELVWCT(SEQ ID NO: 133).

[0073] (In the formula, Xaa1 is a lysine residue, and Xaa3 is homocysteine, and preferably, the homocysteine ​​residues form a disulfide bond with each other).

[0074] Preferred specific examples of IgG binding peptides of formula I include:

[0075] 1) DCAYH(Xaa1)GELVWCT(sequence number 116),

[0076] 2) GPDCAYH(Xaa1)GELVWCTFH(sequence number 117),

[0077] 13)RGNCAYH(Xaa1)GQLVWCTYH(sequence number 128), and

[0078] 14)G(Xaa3)DCAYH(Xaa1)GELVWCT(Xaa3)H (serial number 129),

[0079] As a particularly preferred example, there can be mentioned 2) GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 117) (wherein Xaa1 is a lysine residue, Xaa2 is homocysteine, and preferably the cysteines and / or homocysteine ​​residues form a disulfide bond with each other).

[0080] The IgG binding peptide used in the first embodiment of the present invention can be prepared by combining amino acids that can be both natural amino acids and non-natural amino acids, and applying peptide synthesis methods such as liquid phase synthesis, solid phase synthesis, automatic peptide synthesis, gene recombination or phage display. When synthesizing the peptide, the functional groups of the amino acids used can be protected as needed. For example, they can be carried out according to the methods described in WO2016 / 186206, WO2017 / 217347 and WO2018 / 230257.

[0081] In the first embodiment of the present invention, the IgG binding peptide is characterized in that it is modified with a cross-linking agent, and the IgG binding peptide modified with the cross-linking agent can be used as a linker for modifying an antibody.

[0082] In the case where the IgG binding peptide used in the first embodiment of the present invention is represented by Formula I, Xaa1 is close to a lysine residue in a specific region of IgG Fc. For example, in the case where IgG is trastuzumab, it is close to Lys248 or Lys246, preferably Lys248, based on EU numbering in human IgG Fc. Therefore, by modifying the Xaa1 of the above-mentioned IgG binding peptide with a cross-linking agent, a cross-linking reaction with IgG is performed to form a cross-linked structure between the Xaa1 of the IgG binding peptide and the lysine residue of IgG Fc site-specifically. In this way, by modifying the Xaa1 of the IgG binding peptide with a cross-linking agent and causing it to cross-link with IgG, various compounds can be specifically and simply introduced into IgG. In addition, since compounds can be introduced via IgG binding peptides, compounds of various structures can be introduced into IgG. Moreover, for the method involved in the first embodiment of the present invention, the yield of the obtained product is high, and since there is no mutation of the antibody itself, it also has the advantage of low possibility of reducing antibody function.

[0083] In the first embodiment of the present invention, the "crosslinking agent" is a chemical substance for linking the IgG binding peptide and IgG Fc by covalent bonds. A person skilled in the art can appropriately select the crosslinking agent of the first embodiment of the present invention. For example, cross-linking agents including preferably two or more succinimidyl groups such as DSG (disuccinimidyl glutarate) and DSS (disuccinimidyl suberate); cross-linking agents including preferably two or more imidic acid moieties such as DMA (dimethyl adipimidate·2HCl) and DMP (dimethylpimelimidate·2HCl) and DMS (dimethyl suberimidate·2HCl); and cross-linking agents having SS bonds such as DTBP (dimethyl 3,3'-dithiobispropionimidate·2HCl) and DSP (dithiobis(succinimidyl propionate)). The cross-linking agent is preferably a cross-linking agent having a succinimide group that can bind to the side chain terminal amino group of the amino acid residue constituting the IgG-binding peptide, and DSG and DSS are particularly preferred.

[0084] In the first embodiment of the present invention, the above-mentioned IgG binding peptide can be modified by other functional substances, such as antibodies such as IgA or VHH, markers and / or other agents. The connection of IgG binding peptide and other functional substances can be carried out by methods known to those skilled in the art, such as the reaction of an azido group and dibenzocyclooctyne (dibenzocyclooctyne) or the reaction of a maleimide group and a sulfhydryl group. In the case of being labeled with a marker, the IgG binding peptide forms a complex with IgG, thereby enabling the detection or quantification of IgG via the marker. The marker is not limited, for example, including fluorescent pigments, chemiluminescent pigments, and fluorescent proteins such as biotin and GFP (green fluorescent protein), luminescent proteins and peroxidase enzymes, and the example of a preferred marker is a fluorescent pigment such as fluorescein and FITC, rhodamine derivatives such as rhodamine and tetramethylrhodamine, and fluorescent pigments such as Texas Red (Texas Red). When other drugs are used to modify IgG binding peptides, the drugs are not limited, and examples thereof include anticancer agents such as auristatin, maytansine, doxorubicin, bleomycin or their derivatives; and targeted preparations such as drugs that can bind to receptors on the blood-brain barrier and transfer to the central nervous system, or drugs that can bind to cancer cells and transfer antibodies into cells.

[0085] As one mode of the first embodiment of the present invention, the N-terminus of the above-mentioned IgG binding peptide is modified with a chelating agent capable of chelating a radioactive metal or an atomic group capable of a click reaction. In the first embodiment of the present invention, the chelating agent is not particularly limited as long as it has a site for coordination of the radioactive metal in its structure, and the site for coordination of the radioactive metal is the chelating part. The chelating part is not particularly limited as long as it has a site for coordination of the radioactive metal in the structure, and preferably has a site derived from CB-TE2A (1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid), CDTA (trans-1,2-cyclohexanediaminetetraacetic acid), CDTPA (4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid), DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTMA ((1R,4R,7R,10R)-α,α',α",α"'-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), Heterocyclododecane-1,4,7,10-tetraacetic acid), DOTAM (1,4,7,10-tetra(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane), DOTA-GA (α-(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTP (((1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetra(methylene))tetraphosphonic acid), DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonic acid)), DOTA-4AMP (1,4,7, 10-Tetraazacyclododecane-1,4,7,10-tetrakis(acetamido methylenephosphonic acid), D02P(tetraazacyclododecane dimethanephosphonic acid), deferoxamine (DFO), DTPA(N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine), DTPA-BMA(5,8-bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecyl-13-carboxylic acid), EDTA(2,2',2",2"'-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid), NOTA(1,4,7-triazacyclononane -1,4,7-triacetic acid), NOTP (1,4,7-triazacyclononane-1,4,7-triyltris(methylenephosphonic acid), TETPA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid), TETA (1,4,8,11-tetraazacyclotetradecane-N,N',N",N"'-tetraacetic acid), TTHA (3,6,9,12-tetra(carboxymethyl)-3,6,9,12-tetraazatetradecanedioic acid), HEHA (1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid), 1,2-HOPO (N,N',N",N"'-tetrakis(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane), PEPA (1,4,7,10,13-pentaazacyclopentadecane-N,N',N",N"',N""-pentaacetic acid), H4octapa (N,N'-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N'-diacetic acid), H2bispa2 (6,6'-({9-hydroxy-1,5-bis(methoxycarbonyl)-2,4-di(pyridin-2-yl)-3,7-diazabicyclo[3.3.1]nonane-3,7-diyl}bis(-methylene))picolinic acid), H2dedp a (1,2-[{6-(carboxyl)-pyridin-2-yl}-methylamino] ethane), H2macropa (6-(1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-N,N'-methyl)picolinic acid), H5decapa (N,N"-bis(6-carboxyl-2-pyridylmethyl)-diethylenetriamine-N,N',N"-triacetic acid), H6phospa (N,N'-(methylenephosphonate)-N,N'-[6-(methoxycarbonyl)pyridin-2-yl]-methyl-1,2-diaminoethane), HP-D03A (hydroxypropyltetraazacyclododecanetriacetic acid) or porphyrin, or the structure of a compound represented by the following formula (A). These structures can be appropriately selected according to the type of radioactive metal described later. ,

[0086] [Chemical formula 2]

[0087]

[0088] (In formula (A), R 11 , R 13 and R 14 Each independently comprises -(CH2) p COOH, -(CH2) p C5H5N, -(CH2) p PO3H2, -(CH2) p CONH2 or -(CHCOOH)(CH2) p COOH group, R 12 or R 15 One of them is a hydrogen atom, a carboxyl group or a carboxylalkyl group having 2 or 3 carbon atoms, and the other is a substituent for binding to the above-mentioned IgG-binding peptide, p is an integer of 0 to 3, and in R 12 When R is a substituent for binding to the above-mentioned IgG-binding peptide, 15 For hydrogen atoms, in R 12 When R is not a substituent for binding to the above-mentioned IgG-binding peptide, 15is a substituent for binding to the above-mentioned IgG binding peptide. )

[0089] Specific examples of the structure represented by formula (A) include structures derived from compounds represented by the following formulae (A-1) to (A-12).

[0090] [Chemical formula 3]

[0091]

[0092] [Chemical formula 4]

[0093]

[0094] [Chemical formula 5]

[0095]

[0096] The method of connecting the chelating agent to the IgG binding peptide is well known to those skilled in the art. For example, when connecting the chelating agent to the N-terminus of the IgG binding peptide, it is sufficient to add a reactive group such as N-hydroxysuccinimide ester (NHS), isothiocyanate (ITC), sulfonyl chloride, carboxylic acid chloride, ethylene oxide, alkyl chloride, aldehyde group and carboxylic anhydride to the chelating agent and react it with the amino group at the N-terminus of the IgG binding peptide. Alternatively, the IgG binding peptide containing such a chelating agent can be directly synthesized using a known synthesis method.

[0097] As the radioactive metal, a metal nuclide that emits α-rays, β-rays, or γ-rays, or a combination thereof, can be used. Examples of such radioactive metal nuclides include alkali metals, alkaline earth metals, lanthanides, actinides, transition metals, or radioactive isotopes of metals other than these metals. Among them, from the viewpoint of commercial utilization and improved chelate formation, it is preferred to use a radioactive metal nuclide. 44 Sc, 51 Cr, 57 Co. 58 Co. 60 Co. 59 Fe, 67 Ga, 68 Ga, 64 Cu, 67 Cu, 89 Sr. 89 Zr, 90 Y. 99m Tc, 103 Such as 111 In, 153 Sm, 165 Dy, 166 Ho, 177 Lu, 186Re, 188 Re, 198 Au, 201 Tl, 197 Hg, 203 Hg, 212 Bi, 213 Bi, 212 Pb, 227 Th or 225 Ac. These radioactive metals can be produced according to conventional methods, and are preferably obtained in the form of a solution containing the radioactive metal in an ionized form.

[0098] A person skilled in the art can appropriately select a preferred combination of a radioactive metal and a chelating agent.

[0099] As an atomic group capable of performing a click reaction, an appropriate atomic group can be selected according to the type of click reaction. The click reaction can be performed, for example, by a combination of alkynes and azides, a combination of 1,2,4,5-tetrazines and olefins, etc. In these combinations, one atomic group can be introduced into the N-terminus of the IgG binding peptide, and the other atomic group can be introduced into the chelating agent. As a specific example of a click reaction based on such a combination of atomic groups, a Huisgen cycloaddition reaction or a reverse electron demand Diels-Alder reaction can be cited.

[0100] Specific examples of combinations of atomic groups capable of undergoing a click reaction include, as shown in the following formulas: a combination of an atomic group comprising dibenzylcyclooctyne (DBCO) as an alkyne (Formula (1a)) and an atomic group comprising an azido group as an azide (Formula (2a)); or a combination of an atomic group comprising 1,2,4,5-tetrazine (Formula (1b)) and an atomic group comprising trans-cyclooctene (TCO) as an olefin (Formula (2b)).

[0101] [Chemical formula 6]

[0102]

[0103] (In formula (1a), R1 represents the binding site with the antibody-modified linker or chelating agent, and in formula (2a), R2 represents the binding site with the antibody-modified linker or chelating agent.)

[0104] [Chemical formula 7]

[0105]

[0106] (In formula (1b), one of R3 and R4 represents a binding site with an antibody-modified linker or a chelating agent, and the other represents a hydrogen atom, a methyl group, a phenyl group or a pyridyl group. In formula (2b), R5 represents a binding site with an antibody-modified linker or a chelating agent.)

[0107] The method of linking the atomic group capable of click reaction to the IgG binding peptide is well known to those skilled in the art. For example, the method of introduction can be mentioned as follows: the IgG binding peptide is dissolved in a solution to which a solubilizing agent and a reducing agent, and an acid as required, and an organic solvent solution containing an atomic group of an azide group or trans-cyclooctene (TCO) as an atomic group capable of click reaction is added to the solution, and stirred at room temperature.

[0108] When introducing an azide group-containing atomic group as an atomic group capable of click reaction, a commercially available azide group-introducing reagent is used to introduce an azide group into the N-terminus of the peptide according to a conventional method. Examples of the azide group-introducing reagent used include silyl azide, phosphoric acid azide, alkylammonium azide, inorganic azide, sulfonyl azide, or PEG azide.

[0109] When an atomic group containing TCO is introduced as an atomic group capable of click reaction, TCO is introduced to the N-terminus of the peptide according to a conventional method using a commercially available click chemistry reagent containing TCO.

[0110] When an alkyne, for example, an atomic group containing dibenzylcyclooctyne (DBCO) represented by the above formula (1a) is used as an atomic group capable of click reaction, various commercially available DBCO reagents can be cited. Specifically, for example, DBCO-C6-acid, dibenzylcyclooctyne-amine, dibenzylcyclooctyne-maleimide, DBCO-PEG acid, DBCO-PEG-NHS ester, DBCO-PEG-alcohol, DBCO-PEG-amine, DBCO-PEG-NH-Boc, carboxyrhodamine-PEG-DBCO, sulforhodamine-PEG-DBCO, TAMRA-PEG-DBCO, DBCO-PEG-biotin, DBCO-PEG-DBCO, DBCO-PEG-maleimide, TCO-PEG-DBCO, DBCO-mPEG, etc. can be selected, and dibenzylcyclooctyne-maleimide is preferably used.

[0111] The IgG binding peptides can be modified, for example, by PEGylation (addition of polyethylene glycol) at the N-terminus and amidation at the C-terminus in order to improve their stability. The number of PEG molecules used in PEGylation is not particularly limited, and for example, 1 to 50 molecules, 1 to 20 molecules, 2 to 10 molecules, 2 to 6 molecules, or 4 molecules of PEG can be added.

[0112] The IgG binding peptide modified with a cross-linker, i.e., an antibody modified linker, can be prepared, for example, by reacting the IgG binding peptide obtained by the method described in the above-mentioned item <IgG binding peptide> with a cross-linker. This can be accomplished by selecting the type of amino acid at a specific position in the IgG binding peptide to be modified by the cross-linker and the combination of the cross-linker. For example, for cross-linkers containing a succinimide group such as DSS or DSG, since they react with primary amines present in the side chain of lysine residues and the N-terminus of the polypeptide, by blocking the N-terminus of the IgG binding peptide and reacting it with DSS or DSG, it is possible to specifically modify only the side chain of the lysine residue using DSS or DSG.

[0113] The reaction of the IgG binding peptide with the cross-linking agent is carried out within the range that the yield of the IgG binding peptide, i.e., the antibody modified linker, which is site-specifically modified by the cross-linking agent can be maintained and the hydrolyzate of the antibody modified linker as a by-product can be reduced. Specifically, the reaction of the IgG binding peptide with the cross-linking agent is carried out in a solvent, using a "tertiary amine with a stronger alkalinity than pyridine" as a base and in the presence of the base at a reaction temperature below room temperature. As the solvent used in this reaction, there is no particular limitation as long as it does not adversely affect the reaction, and water, saline, or sodium acetate buffer, ammonium acetate buffer, phosphate buffer, phosphate buffered saline, Tris buffer, HEPES buffer or tetramethylammonium acetate buffer, etc., or water-soluble organic solvents such as alcohols with a carbon number of 1 or more and less than 5, acetonitrile, N,N-dimethylformamide, tetrahydrofuran, dimethyl sulfoxide and acetone, or mixed solvents thereof can be used.

[0114] The “basicity” referred to in the present embodiment can be represented by the pKa of the conjugate acid when the tertiary amine used in the first embodiment of the present invention is used as a base.

[0115] As the "tertiary amine having a stronger basicity than pyridine", a tertiary amine having a pKa of 6.0 or more is preferred (the pKa of pyridine is 5.25). If the alkalinity is weak, the reaction will not proceed sufficiently. The use of a strongly alkaline tertiary amine can be expected to allow the reaction to proceed sufficiently, but from the viewpoint of improving versatility, the pKa is preferably 15.0 or less, and more preferably 8.0 or less. The "tertiary amine having a stronger basicity than pyridine" used in the present invention is preferably a pKa of 6.0 or more and 15.0 or less, and more preferably a pKa of 6.0 or more and 8.0 or less. Specifically, a tertiary alkylamine is preferred, and a tertiary alkylamine having 1 to 10 carbon atoms is more preferred, and it may be a chain alkylamine or a cyclic alkylamine. For example, chain alkylamines such as trimethylamine, triethylamine, diethylmethylamine, methyldipropylamine, methyldiisopropylamine, ethyldimethylamine, dimethylpropylamine, ethylmethylpropylamine, and ethylmethylisopropylamine; cyclic alkylamines such as methylpyrrolidine, ethylpyrrolidine, propylpyrrolidine, isopropylpyrrolidine, butylpyrrolidine, tert-butylpyrrolidine, methylhomopiperidine, ethylhomopiperidine, methylpiperidine, ethylpiperidine, dimethylpiperazine, diethylpiperazine, methylethylpiperazine, N-methylmorpholine, and ethylmorpholine are mentioned. N-methylmorpholine (NMM) is preferred.

[0116] The amount of the tertiary amine having a stronger basicity than pyridine in the present reaction is not particularly limited as long as it can promote the reaction. Based on the molar amount of the IgG binding peptide, the upper limit may be, for example, 20 equivalents or less, 10 equivalents or less, 8 equivalents or less, or 4 equivalents or less, and the lower limit may be, for example, 1 equivalent or more, 2 equivalents or more, 3 equivalents or more, or 4 equivalents or more, preferably 2 equivalents or more and 20 equivalents or less, 4 equivalents or more and 20 equivalents or less, 2 equivalents or more and 10 equivalents or less, 4 equivalents or more and 10 equivalents or less, 2 equivalents or more and 8 equivalents or less, 4 equivalents or more and 8 equivalents or less, or 2 equivalents or more and 4 equivalents or less. If the amount is too small, the reaction will not proceed sufficiently, and if the amount is too large, the amount of hydrolyzate as a by-product increases.

[0117] The amount of the cross-linking agent used in this reaction is not particularly limited as long as the IgG binding peptide can be modified site-specifically by the cross-linking agent, and is usually an excess amount, preferably: based on the molar amount of the IgG binding peptide, as an upper limit, for example, it can be less than 100 equivalents, less than 50 equivalents, less than 40 equivalents, less than 30 equivalents, less than 20 equivalents, less than 15 equivalents or less than 10 equivalents, as a lower limit, for example, it can be more than 5 equivalents, more than 10 equivalents, more than 20 equivalents, more than 25 equivalents or more than 30 equivalents. If it is too little, the reaction becomes insufficient. Since the yield reaches a plateau even if a certain amount of cross-linking agent is used, it is preferably used in an amount of more than 20 equivalents and less than 50 equivalents, more than 20 equivalents and less than 40 equivalents, and more than 20 equivalents and less than 30 equivalents.

[0118] The reaction temperature in this reaction is, for example, below room temperature. Here, "room temperature" refers to the temperature specified in the sixteenth revised edition of the Japanese Pharmacopoeia, usually 1 to 30°C. The reaction temperature can be, for example, below 30°C, below 20°C, or below 10°C, more preferably below 5°C, and further preferably below -5°C. By setting it in this way, the generation of hydrolyzates of antibody-modified linkers as by-products can be further suppressed. In addition, in order to suppress the increase in the required amount of tertiary amines with a stronger alkalinity than pyridine and / or not to make the reaction time too long, the reaction temperature is preferably above -40°C, more preferably above -20°C.

[0119] The reaction time in this reaction is not particularly limited as long as the reaction is fully carried out. It is also different due to the type or amount of the IgG binding peptide, cross-linking agent, tertiary amine (base), and the reaction temperature used, and can be appropriately set according to them. Usually, the reaction time can be less than 250 minutes, less than 200 minutes, less than 180 minutes, less than 150 minutes, less than 120 minutes, and less than 60 minutes. At a higher reaction temperature, the amount of alkali is less and the reaction time is also short. At a lower reaction temperature, the amount of alkali is more and the reaction time is also lengthened.

[0120] After the reaction is completed, the reaction solution can be directly used in the composite step described later, or it can be concentrated or purified by removing the solvent by freeze drying or the like. The purification conditions are not particularly limited, for example, ethyl acetate, isopropyl acetate, acetonitrile, tetrahydrofuran can be used to precipitate the solid, or ultrafiltration, gel filtration chromatography, ion exchange chromatography, affinity chromatography, reverse phase chromatography, high performance liquid chromatography and other chromatography methods can be used. In the case of using reverse phase chromatography, the mobile phase is preferably a mixture of an organic solvent and an acidic aqueous solution, and acetonitrile, ethanol, methanol or 2-propanol as an organic solvent and a mixture of an aqueous solution containing formic acid, acetic acid or trifluoroacetic acid as an acidic aqueous solution can be exemplified, but preferably a mixture of acetonitrile and an aqueous solution containing trifluoroacetic acid. In the case of preserving the antibody modified linker, it is preferably stored below room temperature, more preferably stored below 0°C.

[0121] 2. Method for producing antibody complex

[0122] As another embodiment, the first embodiment of the present invention provides a method for producing an antibody complex, which comprises: a linker modification step, using the above-mentioned method (1. Method for producing an antibody modified linker) to obtain an antibody modified linker; and a complexing step, mixing the above-mentioned antibody modified linker with an antibody, reacting the succinimide group of the antibody modified linker with the side chain terminal amino group of the amino acid residue constituting the antibody, and obtaining a complex of the antibody modified linker and the antibody. The antibody complex only needs to connect more than one molecule of the antibody modified linker to one molecule of the antibody, for example, including an antibody complex formed by connecting one molecule of the antibody modified linker to one molecule of the antibody, or an antibody complex formed by connecting two molecules of the antibody modified linker to one molecule of the antibody.

[0123] The conditions of the composite step are not particularly limited as long as they are conditions under which a cross-linking reaction can occur between the succinimide group of the cross-linking agent possessed by the antibody-modified linker and the side chain terminal amino group of the amino acid residue constituting the antibody. For example, a solution containing the antibody-modified linker obtained after the linker modification step can be mixed with a solution containing the antibody, or a solution containing the antibody-modified linker can be mixed with a solution containing the antibody after solvent replacement with a desired buffer. Solvent replacement can be appropriately carried out by a known method. In addition, the reaction temperature of the composite step is not particularly limited as long as it is a temperature at which the antibody-modified linker is connected to the antibody by a cross-linking reaction. It is preferably carried out under conditions where the antibody can exist stably, and more preferably at a temperature where the antibody-modified linker is not decomposed and the hydrolyzate of the antibody-modified linker is not extremely increased. For example, it can be carried out at room temperature (1°C to 30°C) or room temperature (15°C to 25°C). The composite step is preferably carried out under conditions where the antibody can exist stably, preferably under weakly acidic conditions of pH 5 to 7. As the solvent of the composite step, buffers such as acetic acid buffer, 2-amino-2-(hydroxymethyl)propane-1,3-diol (Tris) buffer, 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid (HEPES) buffer, phosphate buffer, histidine buffer can be used. In addition, known catalysts, known stabilizers such as arginine, or sugars such as sucrose or isotonic agents such as sodium chloride and potassium chloride that are used to promote the cross-linking reaction can be added in appropriate amounts as needed.

[0124] The mixing ratio of the antibody-modified linker and the antibody in the composite step is not particularly limited, and for example, the molar ratio is 1:1 or more and 20:1 or less. The lower limit is preferably 2:1 or more, more preferably 5:1 or more, and the upper limit is more preferably 10:1 or less. In addition, the reaction time of the composite step is not particularly limited, and for example, it is 1 minute or more and 5 hours or less. The lower limit is preferably 10 minutes or more, more preferably 15 minutes or more, and the upper limit is preferably 2 hours or less, more preferably 1 hour or less.

[0125] The manufacture method of the antibody complex can be implemented after the composite step, and the step of purifying the obtained antibody complex as needed is carried out, and impurities, such as unreacted IgG binding peptides, antibody modified joints, antibodies, etc. are separated and the purification of the antibody complex is carried out. The purification conditions at this time are not particularly limited, and for example, purification methods known in the field such as ultrafiltration, gel filtration chromatography, ion exchange chromatography, affinity chromatography, reverse phase chromatography, hydrophobic chromatography, high performance liquid chromatography, etc. can be adopted, and affinity chromatography can be preferably used. Mobile phase can use phosphate buffer, acetate buffer, citrate buffer, glycine buffer, etc., and salts such as ammonium sulfate, sodium chloride, potassium chloride can be appropriately added.

[0126] The first embodiment of the present invention includes the following technical ideas.

[0127] [1] A method for producing an antibody-modified linker, which is a method for producing an antibody-modified linker by reacting an IgG binding peptide with a cross-linking agent, characterized in that the cross-linking agent is a cross-linking agent having a succinimide group that can bind to the side chain terminal amino group of the amino acid residue constituting the IgG binding peptide, and the reaction is carried out in the presence of a tertiary amine with a stronger base than pyridine and at a temperature below room temperature.

[0128] [2] The method for producing an antibody-modified linker according to [1] above, wherein the tertiary amine is a tertiary amine having a pKa of 6.0 or more and 15.0 or less.

[0129] [3] The method for producing an antibody-modified linker according to [2] above, wherein the tertiary amine is a tertiary amine having a pKa of 6.0 or more and 8.0 or less.

[0130] [4] The method for producing an antibody-modified linker as described in [1] to [3] above, characterized in that the reaction is carried out in the presence of a molar amount of the tertiary amine of not less than 2 equivalents and not more than 20 equivalents based on the molar amount of the IgG-binding peptide.

[0131] [5] The method for producing an antibody-modified linker according to any one of [1] to [4] above, wherein the reaction is carried out at a temperature below 5°C.

[0132] [6] The method for producing an antibody-modified linker according to any one of [1] to [4] above, wherein the reaction is carried out at a temperature below -5°C.

[0133] [7] The method for producing an antibody-modified linker according to any one of [1] to [6] above, wherein the cross-linking agent is DSG (disuccinimidyl glutarate) or DSS (disuccinimidyl suberate).

[0134] [8] The method for producing an antibody-modified linker according to any one of [1] to [7] above, wherein the IgG-binding peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues represented by the following formula I.

[0135] (X) 1-3 -C-(X)2-H-(Xaa1)-G-(Xaa2)-LVWC-(X) 1-3 (I)

[0136] (wherein each X is independently any amino acid residue except cysteine,

[0137] C is a cysteine ​​residue,

[0138] H is a histidine residue,

[0139] Xaa1 is a lysine residue,

[0140] G is a glycine residue,

[0141] Xaa2 is a glutamic acid residue, a glutamine residue or an asparagine residue,

[0142] L is a leucine residue,

[0143] V is a valine residue, and

[0144] W is a tryptophan residue. )

[0145] [9] The method for producing an antibody-modified linker according to any one of [1] to [8] above, wherein the N-terminus of the IgG-binding peptide is modified with a chelating agent capable of chelating a radioactive metal or an atomic group capable of undergoing a click reaction.

[0146]

[10] A method for producing an antibody complex, comprising:

[0147] a linker modification step, carrying out the method for producing an antibody-modified linker as described in [1] to [9] above to obtain an antibody-modified linker; and

[0148] In the complexing step, the antibody-modified linker is mixed with the antibody, and the succinimide group of the antibody-modified linker is reacted with the side chain terminal amino group of the amino acid constituting the antibody to obtain a complex of the antibody-modified linker and the antibody.

[0149] (Second embodiment)

[0150] The method for producing an antibody labeling reagent according to the present embodiment comprises reacting a protein or a peptide with the cross-linking reagent (cross-linking agent) in the presence of a base having a stronger basicity than pyridine to bind the amino group in the protein or peptide to the cross-linking agent.

[0151] The "basicity" of this embodiment is synonymous with the "alkalinity" defined in the first embodiment. The base used in this embodiment is a base having a pKa greater than 5.2 (or 5.19, 5.23 or 5.25). A base having a pKa less than 14 (or 14.0) can be preferably used. Alternatively, a base having a pKa of 11 or less can be used. More preferably, a base is a base in a range obtained by combining the maximum and minimum values ​​thereof. Examples of such a base include triethylamine (pKa = 10.75), N,N-diisopropylethylamine, diethylamine or monomethylamine, preferably triethylamine. In this embodiment, pKa is the pKa at room temperature (e.g., 25°C).

[0152] The concentration of the base is not particularly limited as long as it is a concentration that allows the amino group to bind to the cross-linking reagent, and can be appropriately set depending on the types of the base, protein or peptide and cross-linking reagent used, and the concentrations of the protein or peptide and cross-linking reagent, and may be preferably 0.1 to 5%, more preferably 0.5 to 3%, 0.8 to 2%, 0.9 to 1.5% or 1%.

[0153] The solvent used is not particularly limited as long as it does not affect the reaction and can dissolve the protein or peptide and the cross-linking reagent. It is preferably an aprotic polar solvent, for example, dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), chloroform, dichloromethane, diethyl ether, tetrahydrofuran (THF), ethyl acetate, acetone and acetonitrile, and more preferably dimethyl sulfoxide (DMSO) or N,N-dimethylformamide (DMF).

[0154] As a protein or peptide, a peptide that can specifically bind to the Fc region of IgG (Fc binding peptide) is preferred. "IgG" can be IgG of mammals, such as primates such as humans and chimpanzees, experimental animals such as rats, mice and rabbits, domestic animals such as pigs, cattle, horses, sheep and goats, and pets such as dogs and cats, preferably human IgG (IgG1, IgG2, IgG3 or IgG4). As IgG, human IgG1, IgG2 or IgG4, or rabbit IgG is preferred, and human IgG1, IgG2 or IgG4 is particularly preferred. Typically, the "Fc region of IgG" refers to a fragment of the C-terminal side obtained in the form of a product treated with the proteolytic enzyme papain of IgG.

[0155] The Fc-binding peptide is preferably a peptide that binds to a site selected from the group consisting of Lys248, Lys246, Lys338, Lys288, Lys290, Lys360, Lys414 and Lys439 in Fc based on EU numbering and / or its adjacent region, preferably Lys248 and / or its adjacent region, or a peptide that binds to the binding region of protein A. For example, the Fc-binding peptide may be a partial peptide of protein A having Fc-binding ability or a mutant thereof. Specific examples of such peptides are described in International Patent Publication Nos. WO2008 / 054030, WO2013 / 027796, WO2016 / 186206, WO2018 / 230257 and ACS Omega (2019) by Kyohei Muguruma et al.; 4(11): 14390-14397. They can be appropriately prepared according to the methods described in the respective documents.

[0156] Examples of such peptides include the following peptides (i) to (iii).

[0157] (i) A peptide represented by the following formula (I):

[0158] NH2-(Linker)-(X 1 1-3 )-C-(X 2 )-(X 3 )-(X 4 )-(X 5 )-G-(X 6 )-L-(X 7 )-WC-(X 8 1-3 )-(Linker)···(I)

[0159] [In formula (I), each (Linker) is independently the same or different linker, or does not exist. Here, the linker is RRRGS (SEQ ID NO: 136), EEGGS (SEQ ID NO: 137), (GSGGS (SEQ ID NO: 138)) 1-3 or (PEG) 1-10 (Preferably (PEG) 1-8 or (PEG) 2-10 , more preferably (PEG)4),

[0160] 1 to 3 Xs 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and 1 to 3 Xs 8 Each independently represents the same or different amino acid residues,

[0161] Each X 1 , X 2 , X 3 And each X 8 independently represent any amino acid residue other than C that is the same or different,

[0162] X 4 is H, R, S or D,

[0163] X 5 is an amino acid residue selected from the group consisting of K, C, D, E, R, V, F, L, 2-aminosuberic acid, Dpr, Orn, AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu) and Cha,

[0164] X 6 is E, N, R or D,

[0165] X 7 Is I or V.

[0166] It should be noted that Dab, Tle and Cha refer to 2,4-diaminobutyric acid, tert-leucine and β-cyclohexyl-L-alanine, respectively. In addition, Ac and t-Bu refer to having an acetyl group and having a tert-butyl group, respectively.]

[0167] In formula (I), for the purpose of binding, an amino group may be bound to the terminal (-COOH) of the C-terminal amino acid of formula (I) to form a (-C(=O)NH2) group. In addition, in formula (I), the amino group at the N-terminus may be acetylated. In this case, a Lys residue may be introduced at an appropriate position near the N-terminus in the linker.

[0168] Preferred examples of the peptide represented by the above formula (I) include the following peptides.

[0169] [1]X 1 1-3 The amino acid sequence is represented by (S, G, F or absent)-(D, G, A, S, P, Hcy or absent)-(S, D, T, N, E or R).

[0170] [2]X 1 1-3 is D, GPD, R, GPR, SPD, GDD, GPS, SDD, RGN, G-Hcy-D, RGP or GPD.

[0171] [3]X 1 1-3 It is D or GPD.

[0172] [4]X 2 A, S or T.

[0173] [5]X 2 Either A or T.

[0174] [6]X 2 is A.

[0175] [7]X 3 Is Y or W.

[0176] [8]X 3 is Y.

[0177] [9]X 4 For H.

[0178]

[10] X 5 It is an amino acid residue selected from A, R, K, C, D, E, L, 2-aminosuberic acid, Dpr, R, F, 2-aminosuberic acid, Dpr, AcOrn, AcDab, Dab, Nle, Nva, Ala(t-Bu) and Cha.

[0179]

[11] X 5 K, R, AcOrn.

[0180]

[12] X 5 It is an amino acid residue selected from V, Dab, F, R, L, Nva, Nle, Ala (t-Bu) and Cha.

[0181]

[13] X 5 It is an amino acid residue selected from the group consisting of F, R, L, Nva, Nle, Ala (t-Bu) and Cha.

[0182]

[14] X 5 It is an amino acid residue selected from the group consisting of L, Ala(t-Bu) and Cha.

[0183]

[15] X 6 Is E or N.

[0184]

[16] X 6 For E.

[0185]

[17] X 7 is V.

[0186]

[18] X 8 1-3 It is (S, T or D)-(H, G, Y, T, N, D, F, Hcy or not present)-(Y, F, H, M or not present).

[0187]

[19] X 8 1-3It is T, TFH, S, SFH, THH, TFY, TYH or T-Hcy-H.

[0188]

[20] X 8 1-3 It is T or TFH.

[0189] The peptide represented by the above formula (I) may be any one of the above conditions or a combination of two or more thereof, for example, a peptide satisfying the following conditions: [8] and [9]; [8] and

[17] ; [9] and

[17] ; [8], [9] and

[17] ; or a combination of these and any one of

[10] to

[14] .

[0190] More specifically, the following peptides (X 5 Same as above; may have NH2-(Linker)- group at the N-terminus; may also have -NH2 group or -(Linker)-NH2 group at the C-terminus):

[0191] 1)DCAYHX 5 GELVWCT(Serial No.1)

[0192] 2)GPDCAYHX 5 GELVWCTFH (serial number 2)

[0193] 3)RCAYHX 5 GELVWCS (Serial No. 3)

[0194] 4)GPRCAYHX 5 GELVWCSFH (serial number 4)

[0195] 5)SPDCAYHX 5 GELVWCTFH (serial number 5)

[0196] 6)GDDCAYHX 5 GELVWCTFH (serial number 6)

[0197] 7) GPSCAYHX 5 GELVWCTFH (serial number 7)

[0198] 8)GPDCAYHX 5 GELVWCSFH (serial number 8)

[0199] 9)GPDCAYHX 5 GELVWCTHH (serial number 9)

[0200] 10)GPDCAYHX 5 GELVWCTFY (serial number 10)

[0201] 11)SPDCAYHX 5 GELVWCTFY (serial number 11)

[0202] 12)SDDCAYHX 5 GELVWCTFY (serial number 12)

[0203] 13)RGNCAYHX 5 GQLVWCTYH (serial number 13)

[0204] 14)G-Hcy-DCAYHX 5 GELVWCT-Hcy-H (serial number 14)

[0205] 15)RRGPDCAYHX 5 GELVWCTFH (serial number 15)

[0206] 16)DCTYHX 5 GNLVWCT (serial number 16)

[0207] 17)DCAYHX 5 GNLVWCT (serial number 17)

[0208] 18)DCTYHX 5 GELVWCT (serial number 18)

[0209] 19)DCAWHX 5 GELVWCT (serial number 19)

[0210] 20)DCTYTX 5 GNLVWCT (serial number 20)

[0211] 21) DCAYTX 5 GNLVWCT (serial number 21)

[0212] 22)DCSYTX 5 GNLVWCT (serial number 22)

[0213] 23)DCTWTX 5 GNLVWCT (serial number 23)

[0214] 24)DCTYHX 5 GNLVWCT (serial number 24)

[0215] 25) DCTYRX 5 GNLVWCT (serial number 25)

[0216] 26)DCTYSX 5GNLVWCT (serial number 26)

[0217] 27)DCTYTX 5 GNLVWCT (serial number 27)

[0218] 28)DCTYTX 5 GELVWCT (serial number 28)

[0219] 29)DCTYTX 5 GRLVWCT (serial number 29)

[0220] 30)DCTYTX 5 GDLVWCT (serial number 30)

[0221] 31)DCTYTX 5 GNLIWCT (serial number 31)

[0222] 32) DCAYHRGELVWCT (serial number 32)

[0223] 33)GPDCAYHRGELVWCTFH (sequence number 33)

[0224] 34)RCAYHRGELVWCS (serial number 34)

[0225] 35)GPRCAYHRGELVWCSFH (serial number 35)

[0226] 36)SPDCAYHRGELVWCTFH (serial number 36)

[0227] 37) GDDCAYHRGELVWCTFH (serial number 37)

[0228] 38)GPSCAYHRGELVWCTFH (serial number 38)

[0229] 39)GPDCAYHRGELVWCSFH (serial number 39)

[0230] 40)GPDCAYHRGELVWCTHH (serial number 40)

[0231] 41)GPDCAYHRGELVWCTFY (sequence number 41)

[0232] 42)SPDCAYHRGELVWCTFY (serial number 42)

[0233] 43)SDDCAYHRGELVWCTFY (serial number 43)

[0234] 44)DCTYHRGNLVWCT (serial number 44)

[0235] 45)DCAYHRGNLVWCT (serial number 45)

[0236] 46) DCTYHRGELVWCT (serial number 46)

[0237] 47) DCAWHRGELVWCT (serial number 47)

[0238] 48)DCTYTNGNLVWCT (serial number 48)

[0239] 49)DCAYTNGNLVWCT (serial number 49)

[0240] 50)DCSYTNGNLVWCT (serial number 50)

[0241] 51)DCTWTNGNLVWCT (serial number 51)

[0242] 52)DCTYHNGNLVWCT (serial number 52)

[0243] 53)DCTYRNGNLVWCT (serial number 53)

[0244] 54)DCTYSNGNLVWCT (serial number 54)

[0245] 55)DCTYTRGNLVWCT (serial number 55)

[0246] 56)DCTYTNGELVWCT (serial number 56)

[0247] 57)DCTYTNGRLVWCT (serial number 57)

[0248] 58)DCTYTNGDLVWCT (serial number 58)

[0249] 59)DCTYTNGNLIWCT (serial number 59)

[0250] Examples of peptides bound to a linker include peptides having the following structures.

[0251] 60) GSGGS-GPDCAYHRGELVWCTFH-NH2 (serial number 60)

[0252] (PEG)4-GPDCAYHRGELVWCTFH-NH2((PEG)4-SEQ ID NO:33-NH2)

[0253] 61) GSGGS-DCAYHRGELVWCT-NH2 (serial number 61)

[0254] (PEG)4-DCAYHRGELVWCT-NH2((PEG)4-SEQ ID NO.32-NH2)

[0255] In addition, in this embodiment, "peptide" and "peptide capable of specifically binding to the Fc region of IgG" include peptides bound to a functional group Z. For example, the peptide represented by the above formula (I) may be bound to a functional group Z at the front end of (Linker). Examples of such peptides include the following peptides.

[0256] 62) Acetyl-K(Z)-RRRGS-GPDCAYHKGELVWCTFH-NH2 (SEQ ID NO. 62)

[0257] 63) Acetyl-K(Z)-EEGGS-GPDCAYHKGELVWCTFH-NH2 (SEQ ID NO. 63)

[0258] 64)Acetyl-K(Z)-(PEG)4-GPDCAYHKGELVWCTFHNH2(Acetyl-K(Z)-(PEG)4-serial number 64-NH2)

[0259] Alternatively, the following peptides may be peptides in which a maleimide group, a DBCO group, a tetrazine group, or a TCO group is bonded to the N-terminus and / or an NH2 group is bonded to the C-terminus.

[0260] RRRGS-GPDCAYHKGELVWCTFH (serial number 65)

[0261] EEGGS-GPDCAYHKGELVWCTFH (serial number 66)

[0262] (PEG)4-GPDCAYHKGELVWCTFH ((PEG)4-SEQ ID NO: 64)

[0263] In addition, examples of the peptide having a functional group Z bonded to the front end of (Linker) include the following peptides.

[0264] 67) Acetyl-K(Z)RRRGS-DCAYHKGELVWCT-NH2 (Serial No. 67)

[0265] 68) Acetyl-K(Z)EEGGS-DCAYHKGELVWCT-NH2 (Serial No. 68)

[0266] 69)Acetyl-K(Z)-(PEG)4-DCAYHKGELVWCT-NH2(Acetyl-K(Z)-(PEG)4-SEQ ID NO. 69-NH2)

[0267] Alternatively, the following peptides may be peptides in which a maleimide group, a DBCO group, a tetrazine group, or a TCO group is bonded to the N-terminus and / or an NH2 group is bonded to the C-terminus.

[0268] RRRGS-DCAYHKGELVWCT (serial number 70)

[0269] EEGGS-DCAYHKGELVWCT (serial number 71)

[0270] (PEG)4-DCAYHKGELVWCT ((PEG)4-SEQ ID NO: 69)

[0271] (ii) a peptide represented by the following formula (II), or a peptide containing the amino acid sequence of (II) except X 9 ~X 14 Peptides having an amino acid sequence obtained by adding, deleting and / or substituting one or more amino acids at positions other than

[0272] X 9 1-2 NMQX 10 QX 14 RFYEALHDPNLNEEQRNAX 11 IX 12

[0273] SIRDDX 13 -(Linker2)-CONH2······(II)

[0274] [In formula (II), (Linker2) is (GSGGS) 1-3 、(SGSGS) 1-3 or (PEG) 2-10 -Lys (preferably (PEG)4-Lys), SGSGSK, SRRCR, SRRK(Z)R, SRRCRRCRRC, SRRK(Z)RRK(Z)RRK(Z) or (PEG) 1-8 -Lys (preferably (PEG)4-Lys), or absent,

[0275] X 9 1-2 Selected from GF, AF, VF, LF, IF, MF, PF, FF, WF, KF, Orn-F, CF, DF, EF, β-alanine-F, 2-aminosuberic acid-F, Dpr-F, NH2-(PEG) n -CO (where n = 1-50)-F, F, K, Orn, C, D, E, 2-aminosuberic acid, Dpr and Acetyl-K,

[0276] X10 is C or Q,

[0277] X 11 and X 12 Each is independently selected from the group consisting of R, H, D, E, S, T, N, Q, Y and C,

[0278] X 13 C or P, or does not exist

[0279] X 14 is R, C, K or K(Z)].

[0280] The end (-NH2) of the N-terminal amino acid of formula (II) can be acetylated to form a (CH3-C(=O)-NH-) group. In addition, the Cys residue (C) contained in the linker can be linked to other functional molecules via a maleimide group as needed.

[0281] Preferred examples of the peptide having the amino acid sequence represented by the above formula (II) include the following peptides.

[0282]

[21] X 9 Selected from the group consisting of GF, AF, βAlaF, NH2-(PEG)n-CO(n=2-10)-F, F, K, Orn, C, Dpr and Acetyl-K.

[0283]

[22] X 9 Selected from the group consisting of GF, F, K and Acetyl-K.

[0284]

[23] X 10 For Q.

[0285]

[24] X 11 and X 12 Each is independently selected from the group consisting of R, H and E.

[0286]

[25] X 11 For R.

[0287]

[26] X 12 is R or K(Z) (preferably Z is azide).

[0288] More specifically, the peptide having the amino acid sequence represented by the above formula (II) includes the following peptides (wherein the lysine residue contained therein may be bonded with a functional group as required):

[0289] 72)FNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDC (sequence number 72)

[0290] 73)GFNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDC (sequence number 73)

[0291] 74) KNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDC (sequence number 74)

[0292] 75)GFNMQCQKRFYEALHDPNLNEEQRNARIRSIRDDC (sequence number 75)

[0293] 76) KNMQCQKRFYEALHDPNLNEEQRNARIRSIRDDC (sequence number 76)

[0294] 77)FNMQQQRRFYEALHDPNLNEEQRNARIRSIRDD (sequence number 77)

[0295] 78)GKNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDC (sequence number 78)

[0296] 79) Acetyl-FNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SGSGSK-NH2 (Serial No. 79)

[0297] 80) Acetyl-FNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDC-SGSGSK-NH2 (SEQ ID NO. 80)

[0298] 81) Acetyl-FNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-(PEG)4-Lys-NH2 (SEQ ID NO: 81)

[0299] 72-2) Acetyl-FNMQCQRRFYEALHDPNLNEEQRNARIRSIRDDC-(PEG)4-Lys-NH2 (Acetyl-Serial No. 72-(PEG)4-Lys-NH2)

[0300] 82)FNMQQQCRFYEALHDPNLNEEQRNARIRSIRDD-NH2 (serial number 82)

[0301] 83) FNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDC-NH2 (serial number 83)

[0302] 84)FNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SRRK(Z)R-NH2(sequence number 84)

[0303] 85) FNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SRRCR-NH2 (serial number 85)

[0304] 86) FNMQQQCRFYEALHDPNLNEEQRNARICSIRDDP-SRRCRRCRRC-NH2 (sequence number 86),

[0305] 87)FNMQQQK(Z)RFYEALHDPNLNEEQRNARIK(Z)SIRDDP-SRRK(Z)RRK(Z)RRK(Z)-NH2(Serial No. 87)

[0306] 88) Acetyl-KNMQQQCRFYEALHDPNLNEEQRNARIRSIRDD-NH2 (SEQ ID NO. 88)

[0307] 89) Acetyl-KNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDC-NH2 (SEQ ID NO. 89)

[0308] 90)Acetyl-KNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SRRK(Z)R-NH2 (SEQ ID NO. 90)

[0309] 91) Acetyl-KNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SRRCR-NH2 (SEQ ID NO. 91)

[0310] 92) Acetyl-KNMQQQCRFYEALHDPNLNEEQRNARICSIRDDP-SRRCRRCRRC-NH2 (SEQ ID NO. 92)

[0311] 93)Acetyl-KNMQQQK(Z)RFYEALHDPNLNEEQRNARIK(Z)SIRDDP-SRRK(Z)RRK(Z)RRK(Z)-NH2 (Serial No. 93)

[0312] 94)GFNMQQQCRFYEALHDPNLNEEQRNARIRSIRDD-NH2 (sequence number 94)

[0313] 95)GFNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDC-NH2 (serial number 95)

[0314] 96)GFNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SRRK(Z)R-NH2 (sequence number 96)

[0315] 97)GFNMQQQRRFYEALHDPNLNEEQRNARIRSIRDDP-SRRCR-NH2 (serial number 97)

[0316] 98)GFNMQQQCRFYEALHDPNLNEEQRNARICSIRDDP-SRRCRRCRRC-NH2 (serial number 98)

[0317] 99)GFNMQQQK(Z)RFYEALHDPNLNEEQRNARIK(Z)SIRDDP-SRRK(Z)RRK(Z)RRK(Z)-NH2(Serial No. 99)

[0318] 100)FNMQCQZRFYEALHDPNLNEEQRNARIRSIRDDC-NH2 (serial number 100)

[0319] 101) Acetyl-KNMQCQZRFYEALHDPNLNEEQRNARIRSIRDDC-NH2 (SEQ ID NO. 101)

[0320] 102)GFNMQCQK(Z)RFYEALHDPNLNEEQRNARIRSIRDDC-SRRK(Z)R-NH2(sequence number 102)

[0321] 103)FNMQCQK(Z)RFYEALHDPNLNEEQRNARIRSIRDDC-NH2(Serial No. 103)

[0322] 104) Acetyl-KNMQCQK(Z)RFYEALHDPNLNEEQRNARIRSIRDDC-SRRK(Z)R-NH2 (Serial No. 104)

[0323] 105)GFNMQCQK(Z)RFYEALHDPNLNEEQRNARIRSIRDDC-SRRK(Z)RRK(Z)RRK(Z)-NH2(Serial No. 105)

[0324] 106) Acetyl-KNMQCQK(Z)RFYEALHDPNLNEEQRNARIRSIRDDC-SRRK(Z)RRK(Z)RRK(Z)-NH2 (Serial No. 106)

[0325] 107)GFNMQCQK(Z)RFYEALHDPNLNEEQRNARIRSIRDDC-SRRK(Z)RRK(Z)RRK(Z)-NH2 (serial number 107)

[0326] (iii) the following peptide:

[0327] 108) CAWHLGELVWC (serial number 108)

[0328] 109)DCAWHLGELVWCT (serial number 109)

[0329] 110)DCAWHLGELVFCT (serial number 110)

[0330] 111)DCAWHLGELVX 15 CT (serial number 111)

[0331] X 15 =1-naphtoyl, 2-naphtoyl, benzyl or benzothiophene

[0332] 112) CDCAWHLGELVWCTC (serial number 112)

[0333] 113) CAYHLGELVWC (serial number 113)

[0334] 114)DCAYHLGELVWCTF(2-Pya)(Serial No. 114)

[0335] 115)Acetyl-(Lys[Azide])RRRGSGPDCAYHKGELVWCTFH-CONH2) (SEQ ID NO: 115)

[0336] The above-mentioned peptide may also be bonded with a reactive functional group (preferably an azido group) at the N-terminus or C-terminus (preferably the N-terminus) via a linker as needed. For example, the end of the peptide obtained by further bonding 1 to 3 (preferably 2) glutamic acids to the N-terminus and / or C-terminus of the peptide may have a reactive functional group (such as an azido group). The peptide having an azido group can be connected to the peptide by a click reaction with other functional molecules having dibenzylcyclooctyne (DBCO), alkyne, or TCO. In addition, the combination of the peptide and other functional substances can also be carried out using other methods known to those skilled in the art, such as the reaction of a maleimide group with a thiol group.

[0337] The protein or peptide may be cross-linked within the molecule. The protein or peptide may have, for example, one or more (e.g., 1 to 10, 2 to 8, 4 to 6, 1, 2, 3, 4, 5, or 6) cross-linked structures within or between molecules. The cross-linking may be through thiol bonds, for example, a structure in which SH groups are bonded to each other via the following structure.

[0338] [Chemical formula 8]

[0339]

[0340] [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, a phenyl group, or a C1-6 alkyl group]

[0341] For example, the protein may be 500 Da or more, 1000 Da or more, 2000 Da or more, and / or 500,000 Da or less, 200,000 Da or less, or 100,000 Da or less. For example, such a protein may be an enzyme, a glycoprotein (erythropoietin, etc.), a cytokine, a toxin, an adjuvant, a structural protein, an antibody, an Fc fusion protein, an antibody fragment (F(ab')2, Fab', Fab, Fab3, single-chain Fv (scFv), (tandem) bispecific single-chain Fv (sc(Fv)2), single-chain triabody (tribody), nanobody, bivalent VHH, pentavalent VHH, minibody, (double-chain) diabody, tandem diabody, bispecific triabody, bispecific diabody, dual affinity retargeting molecule (DART), triabody (or tribody), tetrabody (or [sc(Fv)2]2), or (scFv-SA)4) disulfide-linked Fv, compact IgG, heavy chain antibody or a polymer thereof, etc.). In addition, for example, the peptide may be a peptide of 5 to 5000 amino acids, 5 to 1000 amino acids, 5 to 500 amino acids, 5 to 100 amino acids, 5 to 50 amino acids, or 10 to 40 amino acids. In addition, the peptide may be either cyclic or linear. Examples of such peptides include vaccines, miniantibodies, antimicrobial peptides, and the like.

[0342] In this embodiment, X m (m is an integer) represents an amino acid. m n " indicates that n amino acids X are combined m , "X" without recording n m " indicates the presence of 1 amino acid X m Here, when n is 2 or more, multiple X mEach of the amino acids may be the same or different independently. In addition, when n is "pq", it means that there are p to q amino acids X. m . In addition, in the amino acid sequence described in the present embodiment, A is an alanine residue, R is an arginine residue, N is an asparagine residue, D is an aspartic acid residue, C is a cysteine ​​residue, Q is a glutamine residue, E is a glutamic acid residue, G is a glycine residue, H is a histidine residue, I is an isoleucine residue, L is a leucine residue, K is a lysine residue, M is a methionine residue, F is a phenylalanine residue, P is a proline residue, S is a serine residue, T is a threonine residue, W is a tryptophan residue, Y is a tyrosine residue, and V is a valine residue. In addition, Hcy is homocysteine, Dpr is diaminopropionic acid, Orn is an ornithine residue, βAla is a β-alanine residue, Dab is a 2,4-diaminobutyric acid residue, Nle is a norleucine residue, Nva is a norvaline residue, Tle is a tert-leucine residue, Ala (t-Bu) is a tert-butylalanine residue, and Cha is a cyclohexylalanine residue. In addition, the amino group in the residues having an amino group in the side chain (lysine residue, ornithine residue, 2,4-diaminobutyric acid residue) can be acetylated as needed. In this embodiment, the acetylated form of natural and artificial amino acids is sometimes accompanied by the prefix Ac recorded on the above-mentioned amino acid characters, unless such an explanation is particularly inconsistent. Even if Ac is not recorded, it is understood that the acetylated form can be included. In this embodiment, K(Z) refers to a lysine residue bound to a functional group, and preferably K(Z) is K(Azide). K(Azide) represents a lysine residue bound to an azide.

[0343] The amino group in the protein or peptide to be bound to the cross-linking reagent can be an amino group present in the above-mentioned protein or peptide, an amino group possessed by a lysine residue, a cysteine ​​residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, diaminopropionic acid or an arginine residue, an amino group of the first amino acid, or an amino group introduced at the carbonyl terminus, preferably an amino group possessed by a lysine residue, a cysteine ​​residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, diaminopropionic acid or an arginine residue, or an amino group of the first amino acid.

[0344] Examples of the cross-linking agent include disuccinimidyl glutarate (DSG), disuccinimidyl suberate (DSS), dimethyl adipimidate dihydrochloride (DMA), dimethyl pimelimimidate dihydrochloride (DMP), dimethyl suberimidate dihydrochloride (DMS), dimethyl 3,3'-dithiobispropionimidate dihydrochloride (DTBP), and dithiobis(succinimidyl propionate) (DSP).

[0345] Throughout the present embodiment, the group represented by "reactive functional group" or "Z" refers to a group that can react and bind to a peptide, protein, nucleic acid or low molecular weight drug under relatively mild conditions. As the reactive functional group, maleimide, thiol or protected thiol, alcohol, acrylate, acrylamide, amine or protected amine, carboxylic acid or protected carboxylic acid, azide, alkyne including cycloalkyne, 1,3-dienes including cyclopentadiene and furan, α-halogenated carbonyl, N-hydroxysuccinimide, N-hydroxysulfosuccinimide, nitrophenyl ester, carbonate, dibenzocyclooctyne (DBCO), tetrazine, methyltetrazine (MTZ), trans-cyclooctene (TCO), azide, carboxyl, tosyl, amino, epoxy, acyl, isothiocyanate, isocyanate, acyl azide, NHS ester, acyl chloride, aldehyde, glyoxal, epoxide, ethylene oxide, carbonate , arylating agents, imide esters, carbodiimides, acid anhydrides, acetyl halides, alkyl halides, maleimides, aziridines, acryloyl derivatives, arylating agents, diazoalkanes, diazoacetyl compounds, carbonyls, ketones, carbodiimides, epoxides, ethylene oxides, carbonyldiimidazoles, N,N'-disuccinimidyl carbonates, N-hydroxysuccinimide chloroformate, alkyl halides, isocyanates, hydrazines, Schiff bases, reductive amination products, Mannich condensation products, diazo derivatives, Mannich condensation products, iodination reaction products, aryl azides, halogenated aryl azides, benzophenones, diazo compounds and diazirine derivatives, etc.

[0346] The method involved in this embodiment may include purifying by size exclusion chromatography after binding the amino group in the protein or peptide with a cross-linking agent. As a support for size exclusion chromatography, a resin that can be used for open column, low pressure, or high pressure chromatography can be used, and the resin is a resin that can use an organic solvent, such as Sephadex, Sepharose, Superdex, Superose, Sephacryl, Biogel, Cellulofine, Toyopearl, Sephadex LH-20, etc. The pore size of the support can preferably be set to More preferably, The particle size of the support is preferably 5 to 500 μm, more preferably 20 to 120 μm. Regarding the column size, an open column preferably has a gel volume of 10 to 1000 mL or more, and a packed column preferably has a gel volume of 3 to 100 mL or more.

[0347] The elution conditions for size exclusion chromatography are preferably 4°C to room temperature, and as the eluent, a volatile strong acid such as 0.01 to 1% TFA, HCl, or an aqueous solution of a volatile weak acid such as 1 to 30% formic acid or acetic acid can be used. Alternatively, a mixed solution of 1 to 100% of a volatile and hydrated organic solvent (CH3CN, MetOH, EtOH, propanol, acetone, etc.) / water containing 0.01 to 1% TFA, HCl, or other volatile strong acid can be used.

[0348] The second embodiment of the present invention includes the following technical ideas.

[0349] [1] A method for producing an antibody labeling reagent, comprising: reacting a protein or peptide with the cross-linking reagent in the presence of a base having a stronger basicity than pyridine, thereby bonding an amino group in the protein or peptide to the cross-linking reagent.

[0350] [2] The method for producing an antibody labeling reagent according to [1], wherein the pKa of the base is greater than 5.2.

[0351] [3] The method for producing an antibody labeling reagent according to [2], wherein the pKa of the base is 14 or less.

[0352] [4] The method for producing an antibody labeling reagent according to [1], wherein the base is triethylamine, N,N-diisopropylethylamine, diethylamine or monomethylamine.

[0353] [5] The method for producing an antibody labeling reagent according to [1], wherein the base is triethylamine.

[0354] [6] The method for producing an antibody labeling reagent according to any one of [1] to [5], wherein the concentration of the base is 0.01 to 5%.

[0355] [7] The method for producing an antibody labeling reagent according to any one of [1] to [6], wherein the protein or peptide is a peptide that can specifically bind to the Fc region of IgG.

[0356] [8] The method for producing an antibody labeling reagent according to [7], wherein the amino acid sequence of the peptide that can specifically bind to the Fc region of IgG is an amino acid sequence described in any one of SEQ ID NOs: 1 to 115.

[0357] [9] A method for producing an antibody labeling reagent as described in any one of [1] to [8], wherein the amino group is an amino group present in the above-mentioned protein or peptide, an amino group possessed by a lysine residue, a cysteine ​​residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, a diaminopropionic acid or an arginine residue, an amino group of the first amino acid, or an amino group introduced at the carbonyl terminus.

[0358]

[10] A method for producing an antibody labeling reagent as described in any one of [1] to [9], wherein the above-mentioned cross-linking reagent is selected from the group consisting of disuccinimidyl glutarate (DSG), disuccinimidyl suberate (DSS), dimethyl adipimelimidate dihydrochloride (DMA), dimethyl pimelimidate dihydrochloride (DMP), dimethyl suberimidate dihydrochloride (DMS), 3,3'-dithiobis(succinimidyl)imidate dihydrochloride (DTBP) and dithiobis(succinimidyl propionate) (DSP).

[0359]

[11] The method for producing an antibody labeling reagent according to any one of [1] to

[10] , comprising purification by size exclusion chromatography.

[0360] The present invention will be described in more detail below using examples etc., but these examples are not intended to limit the scope of the present invention.

[0361] Example

[0362] (Example 1)

[0363] The terms and abbreviations used in this example and their definitions are shown in Table 1.

[0364] [Table 1]

[0365] Terminology and abbreviations definition IgGBP IgG Binding Peptide: IgG Binding Peptide MPA002 Azide-conjugated IgGBP MPA003 MPA002 esterified with succinimidyl glutarate 3arm DOTA peptide IgGBP conjugated with 3arm DOTA DSG Disuccinimidyl glutarate NMM N-Methylmorpholine TEA Triethylamine

[0366] As IgGBP, GPDCAYHKGELVWCTFH (SEQ ID NO: 134, two Cys in the molecule form an SS bond, and the C-terminus is amidated) was used.

[0367] MPA002 is produced according to the method described in WO2017 / 217347, and ethyl azide is bound to the N-terminus of IgGBP via a linker structure having diglycolic acid and 8 ethylene glycol groups. The structure is shown below.

[0368] [Chemical formula 9]

[0369]

[0370] The 3armDOTA peptide was produced according to the method described in WO2017 / 217347, and its structure is shown below.

[0371] [Chemical formula 10]

[0372]

[0373] Experimental Example 1-1: Preparation and evaluation of antibody-modified linkers using IgG-binding peptides modified at the N-terminus with chelating agents

[0374] (Comparative Example 1-1)

[0375] The 3armDOTA peptide (about 1 mg) was dissolved in DMSO (13 μL) to prepare a peptide solution of about 30 mmol / L. To the peptide solution, 13 μL of about 300 mmol / L DSG dissolved in acetonitrile (10 equivalents relative to the 3armDOTA peptide) and 0.2 μL of pyridine (5 equivalents relative to the 3armDOTA peptide) were added to a final concentration of about 0.5%, and the mixture was reacted at 50°C for 6 hours.

[0376] 1 μL of the solution after the reaction was completed was diluted with 0.1% formic acid / DMSO solution (99 μL), and the solution was analyzed under the test conditions described in Table 2.

[0377] [Table 2]

[0378] Test conditions

[0379] Detector: UV spectrophotometer (measurement wavelength: 280nm)

[0380] Chromatographic column: ACQUTTY UPLC CSH C18 1.7μm 2.1×100mm

[0381] Column temperature: 60°C

[0382] Mobile phase A: water / trifluoroacetic acid mixture (1000:1)

[0383] Mobile phase B: acetonitrile / trifluoroacetic acid mixture (1000:1)

[0384] Mobile phase delivery:

[0385]

[0386] Flow rate: 0.3 mL per minute

[0387] Area measurement range: 20 minutes

[0388] Injection volume: 5μL

[0389] The amounts of the unreacted 3armDOTA peptide (IgG-binding peptide), the hydrolyzate, and the succinimidylglutarate-esterified 3armDOTA peptide (antibody-modified linker) were calculated as area percentages (unit: %).

[0390] [Table 3]

[0391] Types of alkali Pyridine pKa of base 5.25 Equivalent number of base 5 Reaction solvent DMSO / ACN Reaction time (minutes) 360 Reaction temperature (℃) 50 IgG binding peptide 1.3 Hydrolyzate 18.0 Antibody Modification Linkers 52.1

[0392] It was found that a large amount of hydrolyzate was generated which was difficult to remove by purification.

[0393] (Example 1-1) Production of Antibody Modified Linkers Using 3armDOTA Peptide

[0394] The 3armDOTA peptide (about 1 mg) was dissolved in DMSO (13 μL) to prepare a peptide solution of about 30 mmol / L. 13.3 μL of 300 mmol / L DSG (10 equivalents relative to the 3armDOTA peptide) and 0.21 μL of NMM (5 equivalents relative to the 3armDOTA peptide) dissolved in acetonitrile were added to the peptide solution and reacted at -20°C for 1 hour. Samples that were reacted at 20°C for 1 hour, at 20°C for 1.3 hours, at 5°C for 3 hours, or at -10°C for 3 hours were also prepared in the same manner.

[0395] 1 μL of each solution after the reaction was completed was diluted with DMSO (49 μL), and the solution was analyzed under the test conditions described in Table 2.

[0396] The amounts of the unreacted 3armDOTA peptide (IgG-binding peptide), the hydrolyzate, and the succinimidylglutarate-esterified 3armDOTA peptide (antibody-modified linker) were calculated as area percentages (unit: %).

[0397] [Table 4]

[0398] Types of alkali NMM ← ← ← ← pKa of base 7.38 ← ← ← ← Equivalent number of base 5 ← ← ← ← Reaction solvent DMSO / ACN ← ← ← ← Reaction time (minutes) 60 80 180 180 60 Reaction temperature (℃) 20 20 5 -10 -20 IgG binding peptide 0.1 0.5 0.7 4.13 8.15 Hydrolyzate 14.7 14.8 13.8 6.98 4.85 Antibody Modification Linkers 58.5 60.7 63.3 75.40 70.21

[0399] The amount of hydrolyzate was reduced without reducing the amount of all target antibody modified linkers produced. Pyridine used as a base in Comparative Example 1-1 is classified as a compound that is relatively weak as a base (pKa: 5.25). On the other hand, the pKa of NMM used as a base in Example 1-1 is 7.38, and its basicity is higher than that of pyridine. From the above results, it can be seen that in order to maintain the yield at the same level as before and reduce the content of the hydrolyzate, it is possible to consider using a base with a stronger basicity than pyridine. In addition, the reaction is fully carried out at a reaction temperature below room temperature.

[0400] Experimental Example 1-2: Preparation and evaluation of antibody-modified linkers using N-terminally azide-modified IgG-binding peptides

[0401] (Comparative Example 1-2)

[0402] MPA002 (about 1 mg) was dissolved in DMSO (20 μL) to prepare a peptide solution of about 19 mmol / L. After adding 20 μL of an acetonitrile solution of DSG (500 mmol / L) to the peptide solution, 0.27 μL of pyridine (6.5 equivalents relative to MPA002) was added to give a final concentration of 0.5%, and the mixture was reacted at 50°C for 3 hours.

[0403] 1 μL of the solution after the reaction was completed was diluted with DMSO (49 μL) and analyzed under the following test conditions.

[0404] [Table 5]

[0405] Test conditions

[0406] Detector: UV spectrophotometer (measurement wavelength: 280nm)

[0407] Chromatographic column: ACQUITY UPLC CSH C18 1.7μm 2.1×100mm

[0408] Column temperature: 60°C

[0409] Mobile phase A: water / trifluoroacetic acid mixture (1000:1)

[0410] Mobile phase B: acetonitrile / trifluoroacetic acid mixture (1000:1)

[0411] Mobile phase delivery:

[0412]

[0413] Flow rate: 0.3 mL per minute

[0414] Area measurement range: 14.5 minutes

[0415] Injection volume: 5μL

[0416] The amounts of unreacted MPA002 (IgG-binding peptide), hydrolyzate, and succinimidylglutarate-esterified MPA002 (MPA003, antibody-modified linker) were calculated as area percentages (unit: %).

[0417] [Table 6]

[0418]

[0419] (Examples 1-2 to 3) Study on reaction temperature and / or base equivalent using MPA002

[0420] MPA002 (about 1 mg) was dissolved in DMSO (20 μL) to prepare a peptide solution of about 19 mmol / L. After adding 20 μL of an acetonitrile solution of DSG (500 mmol / L) to the peptide solution, 0.13 μL (3 equivalents relative to MPA002), 0.21 μL (5 equivalents relative to MPA002), or 0.42 μL (10 equivalents relative to MPA002) of NMM was added, and the mixture was reacted at 10°C, 0°C, -10°C, -20°C, or -30°C for 1, 2, or 3 hours.

[0421] 1 μL of the solution after the reaction was completed was diluted with DMSO (49 μL) and analyzed under the test conditions described in Table 5.

[0422] The amounts of unreacted MPA002 (IgG binding peptide), hydrolyzate, and succinimidylglutarate-esterified MPA002 (MPA003, antibody modified linker) were calculated as area percentage (unit: %). The results of the study on the reaction temperature are shown in Table 7, and the results of the study on the base equivalent are shown in Table 8.

[0423] All the results showed that the amount of hydrolyzate produced was smaller than that of Comparative Example 1-2 shown in Table 6.

[0424] [Table 7]

[0425] Types of alkali NMM ← ← ← ← ← ← ← Reaction temperature (℃) -30 ← -20 ← ← -10 ← 0 Equivalent number of base 5 ← ← ← ← ← ← ← Reaction time (minutes) 120 180 60 120 180 60 120 60 IgG binding peptide 14.72 850 10.45 2.00 041 5.55 0.54 0.92 Hydrolyzate 2.71 2.96 2.95 3.89 4.71 3.42 4.50 4.45 Antibody Modification Linkers 73.12 78.52 76.57 83.34 83.46 80.92 83.94 83.77

[0426] [Table 8]

[0427] Types of alkali NMM ← ← ← ← ← ← ← ← ← ← Reaction temperature (℃) -30 ← ← -20 ← -10 ← ← 0 ← 10 Equivalent number of base 10 ← ← ← ← ← 3 ← ← ← ← Reaction time (minutes) 120 ← 180 60 120 60 120 180 60 120 ← IgG binding peptide 7.52 2.49 0.99 0.83 0.00 0.34 11.11 5.21 11.52 2.65 3.45 Hydrolyzate 3.01 3.34 3.65 3.58 4.56 3.87 3.29 4.16 3.08 4.68 4.80 Antibody Modification Linkers 79.09 82.36 84.79 84.45 83.81 83.23 75.26 80.57 74.55 82.09 81.40

[0428] In addition, when 0.27 μL of NMM (6.5 equivalents relative to MPA002) was added and reacted at 30°C for 1, 2 or 3 hours, the results showed that the area percentage (%) of each component was greater in the hydrolyzate than in the results in Tables 7 and 8, and less in the antibody-modified linker than in the results in Tables 7 and 8.

[0429] (Examples 1-4) Scale-up studies

[0430] It was studied whether the method according to the first embodiment of the present invention can also be applied by expanding the reaction scale.

[0431] MPA002 (about 20 mg) was dissolved in DMSO (400 μL) to prepare a peptide solution of about 19 mmol / L. To the peptide solution was added 400 μL of an acetonitrile solution of DSG (500 mmol / L) (26 equivalents relative to MPA002), and then 2.51 μL of NMM (3 equivalents relative to MPA002) was added, and the mixture was reacted at 0°C for 1 or 2 hours.

[0432] On the other hand, MPA002 (about 1 mg) was dissolved in DMSO (20 μL) to prepare a peptide solution of about 19 mmol / L. To this peptide solution, 20 μL of an acetonitrile solution of DSG (500 mmol / L) was added, followed by 0.13 μL of NMM (3 equivalents to MPA002), and the mixture was reacted at 0°C for 1 or 2 hours.

[0433] 1 μL of each solution after the reaction was completed was diluted with DMSO (49 μL), and the analysis was performed under the conditions described in Table 5.

[0434] The amounts of unreacted MPA002 (IgG-binding peptide), hydrolyzate, and succinimidylglutarate-esterified MPA002 (MPA003, antibody-modified linker) were calculated as area percentages (unit: %).

[0435] [Table 9]

[0436] Reaction temperature (℃) 0℃ ← ← ← IgG binding peptide amount 1mg ← 20mg ← Reaction time (minutes) 60 120 60 120 IgG binding peptide 11.52 2.65 15.09 4.94 Hydrolyzate 3.08 4.68 3.64 4.86 Antibody Modification Linkers 74.55 82.09 71.24 79.13

[0437] All of them showed good results, indicating that the method according to the first embodiment of the present invention can be applied even when the reaction scale is expanded.

[0438] (Example 1-5) Study on the types of bases

[0439] As shown in the above examples, the inventors of the present application found that using NMM, which is a base stronger than pyridine, and lowering the reaction temperature are excellent conditions. Therefore, the reaction was carried out using TEA (pKa: 10.75), which is a base stronger than NMM, and further lowering the reaction temperature.

[0440] MPA002 (about 1 mg) was dissolved in DMSO (20 μL) to prepare a peptide solution of about 19 mmol / L. To the peptide solution, 20 μL (26 equivalents relative to MPA002) of a DSG solution in acetonitrile (500 mmol / L) was added, followed by 0.16 μL (3 equivalents relative to MPA002) of TEA, and the mixture was reacted at -20°C for 2 or 3 hours.

[0441] 1 μL of each solution after the reaction was completed was diluted with DMSO (49 μL), and the analysis was performed under the conditions described in Table 5.

[0442] The amounts of unreacted MPA002 (IgG binding peptide), hydrolyzate, and succinimidylglutarate-esterified MPA002 (MPA003, antibody modified linker) were calculated as area percentage (unit: %). The results are shown in Table 10. As the results when NMM was used as the base, the data for the reaction temperature of -20°C and the reaction time of 120 minutes and 180 minutes are also recorded (Table 7 of Example 1-2).

[0443] [Table 10]

[0444] Types of alkali NMM ← TEA ← pKa of base 7.38 ← 10.72 ← Equivalent number of base 5 ← 3 ← Reaction time (minutes) 120 180 120 180 Reaction temperature (℃) -20 ← ← ← IgG binding peptide 2.00 0.41 12.37 8.50 Hydrolyzate 3.89 4.71 3.68 4.00 Antibody Modification Linkers 83.34 83.46 73.44 76.86

[0445] In all cases, it was confirmed that the amount of hydrolyzate was reduced and a sufficient amount of the target antibody-modified linker could be synthesized.

[0446] From the above results, it can be seen that when preparing antibody-modified linkers, it is preferred to use a base with a stronger alkalinity than pyridine and carry out the binding with the cross-linking agent under the following conditions:

[0447] (1) At a higher reaction temperature, with less base equivalent and shorter reaction time;

[0448] (2) At a lower reaction temperature, a larger base equivalent and a longer reaction time.

[0449] (Example 2)

[0450] (Example 2-1) Preparation of IgG Binding Peptide CCAP Reagent

[0451] Figure 1 The modification pathway of IgG-BP using the DSG-based improvement method is shown in FIG. IgG-BP (IgGBP-N3-RRR: Acetyl-(Lys[Azide])RRRGSGPDCAYHKGELVWCTFH-CONH2) (SEQ ID NO. 115) was reacted with 20-fold molar concentration of DSG at room temperature for 15 minutes in DMSO containing 1% triethylamine. UPLC analysis was performed on samples before and 15 minutes after the addition of DSG under the following conditions.

[0452] That is, 1 nmol of the sample was injected into an ACQUITY UPLC BEH C18 column (1.7 μm, 2.1×100 mm) connected to an ACQUITY SQD-connected UPLC (Waters), and gradient elution was performed with acetonitrile containing 0.1% formic acid from 10% to 40% at a flow rate of 0.2 ml / min. The column temperature was set to 35° C. In addition, the elution was monitored by measuring the absorbance at 280 nm.

[0453] Figure 2 A and Figure 2 B shows the chromatograms of UPLC analysis before the reaction starts and 15 minutes after the reaction starts. Figure 2 In B), the peak of IgG-BP (elution time 11.13 minutes) present before the reaction disappeared, and a peak with an elution time of 12.10 minutes was obtained for the first time. The mass spectrometry analysis of this peak gave a mass value of 2978.34, which is consistent with the target CCAP reagent (theoretical value MW: 2978.36) obtained by SGation of IgG-BP, so it can be seen that IgG-BP has been SGated. Such extremely rapid SGation has never been seen in previous systems using pyridine / DMSO. In addition, although a small amount of SGated hydrolyzate was observed at 11.61 minutes and a small amount of SS reduced form of the SGated CCAP reagent was observed at 12.60 minutes, no other large side reaction peaks were confirmed, so it is believed that side reactions are avoided by reacting in a short time.

[0454] (Example 2-2) Purification of IgG Binding Peptide CCAP Reagent

[0455] In order to remove excess DSG from the reaction solution, size exclusion chromatography was performed using a Sephadex G-10 column equilibrated with 0.1% TFA. That is, the reaction product (about 0.8 mL) diluted 5 times with 0.1% TFA was injected into a Sephadex G-10 column (25×600 mm) connected to an NGC chromatograph (BioRad) at a flow rate of 2.0 mL / min, and the eluate was fractionally recovered. The elution was monitored by measuring the absorbance at 220 and 280 nm.

[0456] The purity of the peptide recovered from the obtained straight-through fraction was checked by reverse phase UPLC. Analysis was performed in the same manner as above using an ACQUITY UPLC BEH C18 column connected to an ACQUITY SQD-connected UPLC (Waters).

[0457] Figure 3 The result of size exclusion chromatography is shown in A. Since SG-modified IgG-BP was recovered in the straight-through fraction and DSG was eluted thereafter, it was found that the two could be completely separated. Figure 3 B shows the results of checking the purity of the peptides recovered from the straight-through fraction using reverse phase UPLC. Although hydrolyzates of SGylated IgG-BP (oxidized form) and SGylated IgG-BP (reduced form) were observed in addition to the target SGylated IgG-BP (oxidized form), the reagent obtained was about 78% pure, and it can be seen that there is no problem with the reactivity when actually reacting with IgG. SGylated IgG-BP (reduced form) was determined to be an impurity, which is a substance contained in the raw material stage ( Figure 2 The peak at 11.65 minutes of A of the present invention is considered to be a peak at 11.65 minutes of A of the present invention. It is believed that in the future, by using a high-purity raw material (oxidized form of IgG-BP), a CCAP reagent can be synthesized with high purity. In addition, although detailed data are not shown, when calculated based on the raw material peptide, the yield of the CCAP reagent of IgG-BP obtained by the SG reaction of the conventional method is about 50%, while the yield of the CCAP reagent of IgG-BP obtained by the improved method is about 65%.

[0458] (Example 2-3) Preparation of Z33 peptide CCAP reagent

[0459] like Figure 4As shown, a Z33-based CCAP reagent was also prepared using a modified method. The Z33-38 azidated peptide was subjected to reverse phase UPLC under the following conditions. That is, the sample was injected into an ACQUITY UPLC BEHC18 column (1.7 μm, 2.1×100 mm) connected to an ACQUITY SQD-connected UPLC (Waters), and gradient eluted with acetonitrile containing 0.1% formic acid from 10% to 40% at a flow rate of 0.2 ml / min. The column temperature was set to 35°C, and the elution was monitored by absorbance measurement at 280 nm.

[0460] like Figure 5 As shown in A, mass spectrometry analysis showed that Z33-38azide was a peak observed at 11.43 minutes. Figure 1 The peptide was reacted with DSG under the same conditions as IgG-BP (room temperature, 15 minutes) and subjected to UPLC. The raw material disappeared and the target SGZ33-38 azide ( Figure 5 The reaction product was diluted 5-fold with 0.1% TFA (about 0.4 mL) and applied to a Sephadex G-10 column ( Figure 6 A), the straight-through fraction was recovered as a CCAP reagent. The purity of the obtained CCAP reagent was analyzed by reverse phase UPLC.

[0461] The results are shown in Figure 6 B. The chromatogram shows that the purity of the target SGated Z33-38 azide is 89%. In addition, when calculated based on the raw material peptide, the yield of the CCAP reagent of Z33 obtained by the SGation reaction of the conventional method is about 30%, while the yield of the improved method is about 50%.

[0462] (Example 2-4) Study on reaction time and base equivalent using IgGBP-N3-RRR

[0463] IgGBP-N3-RRR was dissolved in DMSO (25 μl) to prepare an approximately 14 mM peptide solution. After adding 10 μL of a 1 M DSG DMSO solution to the peptide solution (final concentration of approximately 280 mM), 0.21 μL (3 equivalents relative to the peptide), 0.35 μL (5 equivalents relative to the peptide), 0.46 μL (6.5 equivalents relative to the peptide), or 0.61 μL (8.76 equivalents relative to the peptide) of TEA were added, and the mixture was reacted at room temperature for 15 minutes, 1 hour, or 3 hours, respectively.

[0464] 2 μL of each solution after the reaction was completed was diluted with 10% formic acid (18 μL), and analyzed in the same manner as in Example 2-1.

[0465] When 3 equivalents, 5 equivalents, 6.5 equivalents or 8.76 equivalents of TEA were reacted with the peptide for 15 minutes, 1 hour or 3 hours, the target SGylated IgG-BP (oxidized form) was obtained in high yield.

[0466] Since the amount of the hydrolyzate tends to increase as the reaction time becomes longer, in the present invention, a more excellent effect is exhibited by a reaction in a shorter time.

[0467] In addition, there is a tendency that the amount of hydrolyzate increases as the number of equivalents of TEA increases.

[0468] The above embodiments are used to illustrate the present invention, but are not intended to limit the scope of the present invention. That is, the scope of the present invention is represented by the claims rather than the embodiments. Moreover, various modifications implemented within the scope of the claims and within the meaning of the invention equivalent thereto are deemed to be within the scope of the present invention.

[0469] The contents of all publications mentioned herein, including patents and patent application specifications, are fully incorporated into this specification by reference to the same extent as if expressly stated.

[0470] This application is based on Japanese Patent Application No. 2022-037732 and Japanese Patent Application No. 2022-038459, which were respectively applied for in Japan on March 11, 2022, and all the contents of these applications are included in this specification.

[0471] The present invention is useful for modification of Fc-containing molecules, production of modified Fc-containing molecules and Fc-containing molecule modification reagents, and research reagents.

Claims

1. A method for producing a Fc-containing molecule modification reagent, comprising: The protein or peptide is reacted with a cross-linking agent in the presence of a base having a stronger basicity than pyridine, so that the amino group in the protein or peptide is bound to the cross-linking agent.

2. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The protein or peptide is an IgG binding peptide, The cross-linking agent is a cross-linking agent having a succinimide group that can bind to the side chain terminal amino group of the amino acid residue constituting the IgG binding peptide, The base is a tertiary amine, The reaction is carried out below room temperature.

3. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The tertiary amine is a tertiary amine having a pKa of 6.0 or more and 15.0 or less.

4. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The tertiary amine is a tertiary amine having a pKa of 6.0 or more and 8.0 or less.

5. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The reaction is carried out in the presence of the tertiary amine in a molar amount of 2 to 20 equivalents based on the molar amount of the IgG-binding peptide.

6. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The reaction is carried out at below 5°C.

7. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The reaction is carried out below -5°C.

8. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The cross-linking agent is DSG (disuccinimidyl glutarate) or DSS (disuccinimidyl suberate).

9. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The IgG binding peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues represented by the following formula I, (X) 1-3 -C-(X)2-H-(Xaa1)-G-(Xaa2)-LVWC-(X) 1-3 (I) wherein each X is independently any amino acid residue other than cysteine, C is a cysteine ​​residue, H is a histidine residue, Xaa1 is a lysine residue, G is a glycine residue, Xaa2 is a glutamic acid residue, a glutamine residue or an asparagine residue, L is a leucine residue, V is a valine residue, and W is a tryptophan residue.

10. The method for producing an Fc-containing molecule modification reagent according to claim 2, wherein: The N-terminus of the IgG binding peptide is modified with a chelating agent capable of chelating radioactive metals or an atomic group capable of undergoing a click reaction.

11. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The pKa of the base is greater than 5.

2.

12. The method for producing an Fc-containing molecule modification reagent according to claim 11, wherein: The pKa of the base is 14 or less.

13. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The base is triethylamine, N,N-diisopropylethylamine, diethylamine or monomethylamine.

14. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The base is triethylamine.

15. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The concentration of the alkali is 0.01-5%.

16. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The protein or peptide is a peptide that can specifically bind to the Fc region of IgG.

17. The method for producing an Fc-containing molecule modification reagent according to claim 16, wherein: The amino acid sequence of the peptide that can specifically bind to the Fc region of IgG is an amino acid sequence described in any one of SEQ ID NOs: 1 to 115.

18. The method for producing an Fc-containing molecule modification reagent according to claim 17, wherein: The amino group is an amino group possessed by a lysine residue, a cysteine ​​residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, a diaminopropionic acid or an arginine residue present in the protein or peptide, an amino group of the first amino acid, or an amino group introduced at the carbonyl terminal.

19. The method for producing an Fc-containing molecule modification reagent according to claim 1, wherein: The crosslinking agent is selected from the group consisting of disuccinimidyl glutarate (DSG), disuccinimidyl suberate (DSS), dimethyl adipimidate dihydrochloride (DMA), dimethyl pimelimidate dihydrochloride (DMP), dimethyl suberimidate dihydrochloride (DMS), dimethyl 3,3'-dithiobis(propanoic acid) dihydrochloride (DTBP) and dithiobis(succinimidyl propionate) (DSP).

20. The method for producing an Fc-containing molecule modification reagent according to claim 1, further comprising purification by size exclusion chromatography.

21. A method for producing a composite, comprising: A linker modification step, comprising carrying out the method for producing an Fc-containing molecule modification reagent according to any one of claims 1 to 20 to obtain an Fc-containing molecule modification reagent; as well as The complexing step comprises mixing the Fc-containing molecule modifying reagent and the Fc-containing molecule, allowing the Fc-containing molecule modifying reagent to react with the side chain terminal amino group of the amino acid constituting the Fc-containing molecule to obtain a complex of the Fc-containing molecule modifying reagent and the Fc-containing molecule.